The July 2026 edition of the 1Cell.Ai Newsletter explores a pivotal moment in precision oncology, when emerging evidence becomes clinical practice. This issue unpacks the latest NCCN Bladder Cancer guideline update endorsing ctDNA-based minimal residual disease (MRD) testing for treatment...
ASCO 2026 delivered a defining moment for precision oncology, and the 1Cell.Ai June 2026 Edition Newsletter captures why. From landmark trial data reshaping treatment sequencing to a deeper understanding of how tumours evolve resistance in real time, this month’s research...
The fast-moving world of precision oncology demands an operational engine that is just as sophisticated as the science behind it. In the May 2026 edition of the 1Cell.Ai newsletter, CEO Mohan Uttarwar introduces a purposeful organizational transformation. Led by industry...